Inflammatory Bowel Disease



Inflammatory bowel disease (IBD) is a chronic, often debilitating illness. The three subtypes are Crohn’s disease, ulcerative colitis, and indeterminate colitis. Classically, IBD is thought of as having two distinct peaks of incidence; One occurs between age 21 and 30 and the other in older patients. Though the concept of a bimodal distribution has recently been challenged, there are clear distinctions to be made between older and younger IBD patients. These two groups have significant differences in epidemiology, diagnosis, treatment, and outcomes. These differences are important for clinicians and can help direct management of these patients.


Inflammatory Bowel Disease Ulcerative Colitis Inflammatory Bowel Disease Patient Ischemic Colitis Purine Analog 


  1. 1.
    No authors listed. Wilhelm Fabry (1560–1624)—the other Fabricus. JAMA. 1964;190:933.Google Scholar
  2. 2.
    Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. A pathological and clinical entity. JAMA. 1932;99(16):1323–9.CrossRefGoogle Scholar
  3. 3.
    Wilks S. Morbid appearances in the intestine of Miss Bankes. Lond Med Times Gazette. 1859;2:264–5.Google Scholar
  4. 4.
    De Dombal FT. Ulcerative colitis: definition, historical background, aetiology, diagnosis, natural history and local complications. Postgrad Med J. 1968;44(515):684–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Roth MP, Petersen GM, McElree C, et al. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology. 1989;97(4):900–4.PubMedGoogle Scholar
  6. 6.
    Calkins BM, Lilienfeld AM, Garland CF, et al. Trends in incidence of ulcerative colitis and Crohn’s disease. Dig Dis Sci. 1984;29(10):913–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Jackson JF, Kornbluth A. Do black and Hispanic Americans with inflammatory bowel disease (IBD) receive inferior care compared with white Americans? Uneasy questions and speculations. Am J Gastroenterol. 2007;102(7):1343–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.PubMedCrossRefGoogle Scholar
  9. 9.
    Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46(3):336–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114(6):1161–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Brandt LJ. Gastrointestinal disorders of the elderly. New York: Raven; 1984.Google Scholar
  12. 12.
    Lapidus A, Bernell O, Hellers G, et al. Incidence of Crohn’s disease in Stockholm County 1955–1989. Gut. 1997;41(4):480–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Molinié F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988–1999). Gut. 2004;53(6):843–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Ott C, Obermeier F, Thieler S, et al. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Eur J Gastroenterol Hepatol. 2008;20(9):917–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Jang ES, Lee DH, Kim J, et al. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. 2009;56(94–95):1304–9.PubMedGoogle Scholar
  16. 16.
    Wilson J, Hair C, Knight R, et al. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis. 2010;16(9):1550–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Zheng JJ, Zhu XS, Huangfu Z, et al. Prevalence and incidence rates of Crohn’s disease in mainland China: a meta-analysis of 55 years of research. J Dig Dis. 2010;11(3):161–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Rönnblom A, Samuelsson SM, Ekbom A. Ulcerative colitis in the county of Uppsala 1945–2007: incidence and clinical characteristics. J Crohns Colitis. 2010;4(5):532–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Fujimoto T, Kato J, Nasu J, et al. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981–2000. Eur J Gastroenterol Hepatol. 2007;19(3):229–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Sonnenberg A. Age distribution of IBD hospitalization. Inflamm Bowel Dis. 2010;16(3):452–7.PubMedGoogle Scholar
  21. 21.
    Das KM, Biancone L. Is IBD an autoimmune disorder? Inflamm Bowel Dis. 2008;14 Suppl 2:S97–101.PubMedCrossRefGoogle Scholar
  22. 22.
    Orholm M, Binder V, Sørensen TI, et al. Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol. 2000;35(10):1075–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124(7):1767–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Monsén U, Broström O, Nordenvall B, et al. Prevalence of inflammatory bowel disease among relatives of patients with ulcerative colitis. Scand J Gastroenterol. 1987;22(2):214–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Fielding JF. The relative risk of inflammatory bowel disease among parents and siblings of Crohn’s disease patients. J Clin Gastroenterol. 1986;8(6):655–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Wagtmans MJ, Verspaget HW, Lamers CB, et al. Crohn’s disease in the elderly: a comparison with young adults. J Clin Gastroenterol. 1998;27(2):129–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Polito JM, Childs B, Mellits ED, et al. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111(3):580–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12 Suppl 1:S3–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122(4):867–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Fiedler T, Büning C, Reuter W, et al. Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn’s disease. Eur J Clin Pharmacol. 2007;63(10):917–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Nohara H, Inoue N, Hibi T, et al. Association between the interleukin-1 receptor antagonist polymorphism and ulcerative colitis with younger age at diagnosis. Immunol Lett. 2003;90(1):53–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat Genet. 2008;40(6):710–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonysynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG 16 L1. Nat Genet. 2007;39(2):207–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn’s disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39(5):596–604.PubMedCrossRefGoogle Scholar
  37. 37.
    Probert CS, Jayanthi V, Pinder D, et al. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992;33(5):687–93.PubMedCrossRefGoogle Scholar
  38. 38.
    Jayanthi V, Probert CS, Pinder D, et al. Epidemiology of Crohn’s disease in Indian migrants and the indigenous population in Leicestershire. Q J Med. 1992;82(298):125–38.PubMedGoogle Scholar
  39. 39.
    Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second-generation South Asians in Leicester (1991–1994). Am J Gastroenterol. 1999;94(10):2918–22.PubMedGoogle Scholar
  40. 40.
    Zvidi I, Hazazi R, Birkenfeld S, et al. The prevalence of Crohn’s disease in Israel: a 20-year survey. Dig Dis Sci. 2009;54(4):848–52.PubMedCrossRefGoogle Scholar
  41. 41.
    Birkenfeld S, Zvidi I, Hazazi R, et al. The prevalence of ulcerative colitis in Israel: a twenty-year survey. J Clin Gastroenterol. 2009;43(8):743–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut. 1996;39(5):690–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991;100(1):143–9.PubMedGoogle Scholar
  44. 44.
    Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease. Mayo Clin Proc. 2006;81(11):1462–71.PubMedCrossRefGoogle Scholar
  45. 45.
    Silverstein MD, Lashner BA, Hanauer SB, et al. Cigarette smoking in Crohn’s disease. Am J Gastroenterol. 1989;84(1):31–3.PubMedGoogle Scholar
  46. 46.
    Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn’s disease: a meta analysis of observational studies. Int J Colorectal Dis. 2008;23(12):1213–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Boyko EJ, Koepsell TD, Perera DR, et al. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med. 1987;316(12):707–10.PubMedCrossRefGoogle Scholar
  48. 48.
    Riegler G, Tartaglione MT, Carratú R, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci. 2000;45(3):462–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Rutgeerts P, D’Haens G, Hiele M, et al. Appendectomy protects against ulcerative colitis. Gastroenterology. 1994;106(5):1251–3.PubMedGoogle Scholar
  50. 50.
    Andersson RE, Olaison G, Tysk C, et al. Appendectomy and ­protection against ulcerative colitis. N Engl J Med. 2001;344(11):808–14.PubMedCrossRefGoogle Scholar
  51. 51.
    Kaplan GG, Jackson T, Sands BE, et al. The risk of developing Crohn’s disease after an appendectomy: a meta-analysis. Am J Gastroenterol. 2008;103(11):2925–31.PubMedCrossRefGoogle Scholar
  52. 52.
    Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn’s disease. Gastroenterology. 2000;119(1):23–31.PubMedCrossRefGoogle Scholar
  53. 53.
    Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004;126(2):414–24.PubMedCrossRefGoogle Scholar
  54. 54.
    Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115(4):822–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Das KM, Kadono Y, Fleischner GM. Antibody-dependent cell-mediated cytotoxicity in serum samples from patients with ulcerative colitis. Relationship to disease activity and response to total colectomy. Am J Med. 1984;77(5):791–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Yonamine Y, Watanabe M, Kinjo F, et al. Generation of MHC class 1-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis. J Clin Immunol. 1999;19(1):77–85.PubMedCrossRefGoogle Scholar
  57. 57.
    Ebert EC, Geng X, Bajpai M, et al. Antibody to tropomyosin isoform 5 and complement induce the lysis of colonocytes in ulcerative colitis. Am J Gastroenterol. 2009;104(12):2996–3003.PubMedCrossRefGoogle Scholar
  58. 58.
    Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27(8):617–24.PubMedCrossRefGoogle Scholar
  59. 59.
    Pappo I, Zamir O, Freund HR. Is Crohn’s disease different in the elderly? Harefuah. 1997;132(2):86–8, 151.Google Scholar
  60. 60.
    Freeman HJ. Crohn’s disease initially diagnosed after age 60 years. Age Ageing. 2007;36(5):587–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Lee JH, Cheon JH, Moon CM, et al. Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older? Digestion. 2010;81(4):237–43.PubMedCrossRefGoogle Scholar
  62. 62.
    Zimmerman J, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. J Clin Gastroenterol. 1985;7(6):492–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Triantafillidis JK, Emmanouilidis A, Pomonis E, et al. Ulcerative colitis in the elderly: clinical patterns and outcome in 51 Greek patients. J Gastroenterol. 2001;36(5):312–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):371–83.PubMedCrossRefGoogle Scholar
  65. 65.
    Das KM, Dubin R. Clinical pharmacokinetics of sulfasalazine. Clin Pharmacokinet. 1976;1:406–25.PubMedCrossRefGoogle Scholar
  66. 66.
    Das KM, Sternlieb I. Salicylazosulfapyridine in inflammatory bowel disease. Am J Dig dis. 1975;20:971–6.Google Scholar
  67. 67.
    Das KM, Eastwood MA, McManus JP, et al. Adverse reactions ­during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289(10):491–5.PubMedCrossRefGoogle Scholar
  68. 68.
    McQuaid KR. Chapter 62: drugs used in the treatment of gastrointestinal disease. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic & clinical pharmacology. New York: McGraw Hill Medical; 2009.Google Scholar
  69. 69.
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345–53.PubMedCrossRefGoogle Scholar
  70. 70.
    Kao J, Kwok K, Das KM. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended release mesalamine. J Clin Gastroenterol. 2010;44(8):531–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Das KK, Bajpai M, Kong Y, et al. Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol. 2009;76(1):183–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137(2):512–7, 517.e1–2.Google Scholar
  73. 73.
    Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43.Google Scholar
  74. 74.
    Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low to medium-dose oral glucorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–8.Google Scholar
  75. 75.
    Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol. 1997;92(3):461–4.PubMedGoogle Scholar
  76. 76.
    Jones HW, Hoare AM. Does ulcerative colitis behave differently in the elderly? Age Ageing. 1988;17(6):410–4.PubMedCrossRefGoogle Scholar
  77. 77.
    Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.PubMedCrossRefGoogle Scholar
  78. 78.
    Singleton JD, Conyers L. Warfarin and azathioprine: an important drug interaction. Am J Med. 1992;92(2):217–9.Google Scholar
  79. 79.
    Kroger AT, Sumaya CV, Pickering LK, et al. General recommendations on immunization: recommendations of the ADvisory Committee on Immunization Practices (ACIP), MMWR. 2011;60(2):1–64.Google Scholar
  80. 80.
    Sandborn W, Rutgeerts P, Reinisch W, et al. SONIC: a randomized double-blind, controlled trial comparing infliximab plus asathiprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. Am J Gastroenterol. 2008;103:S436.Google Scholar
  81. 81.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.Google Scholar
  82. 82.
    Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al. Precise 2 study investigators: maintenance therapy with cerolizumab pegol for Crohn’s disease. New Eng J Med. 2007;357(3):239–50.Google Scholar
  83. 83.
    Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15(2):182–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg. 2003;186(5):514–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Norris B, Solomon MJ, Eyers AA, et al. Abdominal surgery in the older Crohn’s population. Aust N Z J Surg. 1999;69(3):199–204.PubMedCrossRefGoogle Scholar
  87. 87.
    Nicholls RJ, Clark DN, Kelso L, et al. Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis. Aliment Pharmacol Ther. 2010;31(12):1310–21.PubMedCrossRefGoogle Scholar
  88. 88.
    Ha C, Newberry R, Stone C, et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8(8):682–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Karvellas CJ, Fedorak RN, Hanson J, et al. Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Can J Gastroenterol. 2007;21(7):443–6.PubMedGoogle Scholar
  90. 90.
    Oikonomou I, Das KM. Extraintestinal manifestations of IBD. In: Bayless TM, Hanauer SB, editors. Advanced therapy in inflammatory bowel disease. Shelton, Conn: People’s Medical Publishing House, USA;2011. p. 519–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of MedicineUMDNJ-Robert Wood Johnson Medical SchoolNew BrunswickUSA
  2. 2.Division of Gastroenterology and Hepatology, Department of Medicine, Crohn’s and Colitis Center of New JerseyUMDNJ-Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations